首页> 外文期刊>OncoTargets and therapy >Identification of genomic expression differences between right-sided and left-sided colon cancer based on bioinformatics analysis
【24h】

Identification of genomic expression differences between right-sided and left-sided colon cancer based on bioinformatics analysis

机译:基于生物信息学分析鉴定右侧和左侧结肠癌的基因组表达差异

获取原文
           

摘要

Introduction: More and more findings have demonstrated that right-sided colon cancers (RCC) and left-sided colon cancers (LCC) are distinct clinical and biological entities and suggest that they should be treated as different diseases. However, the reasons why RCC and LCC harbor different clinical and biological features remain unclear. Materials and methods: To identify the genomic expression differences between RCC and LCC and uncover the mechanisms underlying these differences, we chose the gene expression profiles of GSE14333 from the Gene Expression Omnibus (GEO) database as an object of study. Then, a systematic and integrative bioinformatics analysis was performed to research the possible mechanism of the differentially expressed (DE) genes from the Gene Expression Omnibus dataset including gene ontology (GO) analysis, pathway enrichment analysis, protein–protein interaction (PPI) network construction, and module analysis. Totally, we extracted 3,793 DE genes from samples of colon cancer including 1,961 genes upregulated in RCC and 1,832 genes upregulated in LCC from the selected dataset. Results: The results of GO and pathway enrichment analysis indicated that RCC and LCC could predispose to different pathways regulated by different genes. Based on the PPI network, PCNA , TP53 , HSP90AA1 , CSNK2A1 , UBB , LRRK2 , ABL1 , PRKACA , CAV1 , and JUN were identified as the key hub genes. Also, significant modules were screened from the PPI network. Conclusion: In conclusion, the present study indicated that the identified genes and pathways may promote new insights into the underlying molecular mechanisms contributing to the difference between RCC and LCC and might be used as specific therapeutic targets and prognostic markers for the personalized treatment of RCC and LCC.
机译:简介:越来越多的研究结果表明,右侧结肠癌(RCC)和左侧结肠癌(LCC)是不同的临床和生物学实体,建议应将它们视为不同的疾病。但是,RCC和LCC具有不同的临床和生物学特征的原因仍不清楚。材料和方法:为了鉴定RCC和LCC之间的基因组表达差异并揭示这些差异的潜在机制,我们从基因表达综合(GEO)数据库中选择了GSE14333的基因表达谱作为研究对象。然后,进行了系统,综合的生物信息学分析,以研究来自Gene Expression Omnibus数据集中差异表达(DE)基因的可能机制,包括基因本体论(GO)分析,途径富集分析,蛋白质-蛋白质相互作用(PPI)网络构建以及模块分析。我们从选定的数据集中共从结肠癌样本中提取了3,793个DE基因,包括1,961个在RCC中上调的基因和1,832个在LCC中上调的基因。结果:GO和通路富集分析结果表明,RCC和LCC可能倾向于受不同基因调控的不同通路。基于PPI网络,已确定PCNA,TP53,HSP90AA1,CSNK2A1,UBB,LRRK2,ABL1,PRKACA,CAV1和JUN是关键的中枢基因。此外,还从PPI网络中筛选出重要模块。结论:总之,本研究表明,所鉴定的基因和途径可能促进对导致RCC和LCC差异的潜在分子机制的新见解,并且可以用作RCC和LCC个性化治疗的特定治疗靶点和预后标志物LCC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号